Milrinon Tillomed (Milrinone)

Milrinone, the active ingredient in Milrinon Tillomed, is a phosphodiesterase‑3 (PDE3) inhibitor presented as an intravenous solution for use in acute cardiac care. It increases cardiac contractility and promotes vasodilation, making it useful in the management of acute decompensated heart failure and cardiogenic shock in adult patients. Administration is performed under strict medical supervision in a monitored setting.

GNH USA supplies Milrinon Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and intensive‑care units worldwide, ensuring quality‑assured product availability for critical care settings.

Milrinone is a phosphodiesterase‑3 inhibitor used in acute cardiac failure management.

- Acute decompensated heart failure: improves cardiac output and reduces filling pressures. - Cardiogenic shock: provides inotropic support and systemic vasodilation. - Low cardiac output syndrome after cardiac surgery: enhances myocardial performance.

Milrinone may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hypotension: drop in blood pressure due to vasodilation. - Headache: often related to vascular changes. - Arrhythmias: premature beats or tachycardia. - Nausea: gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe hypotension: potentially life‑threatening drop in pressure. - Ventricular arrhythmias: dangerous heart rhythm disturbances. - Myocardial ischemia: reduced blood flow to heart muscle. - Allergic reactions: rash, bronchospasm, or anaphylaxis.

Milrinon Tillomed requires careful clinical monitoring and adherence to safety guidelines.

- Blood pressure monitoring: watch for hypotension during infusion. - Cardiac rhythm surveillance: detect arrhythmias promptly. - Dose adjustment in renal impairment: reduce infusion rate as needed. - Caution in recent myocardial infarction: assess risk of ischemia. - Contraindicated in severe aortic stenosis: avoid due to fixed outflow obstruction. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Milrinone can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid): - Other PDE3 inhibitors: additive inotropic effect and profound hypotension. - Strong CYP3A4 inhibitors: increased plasma concentrations of milrinone. - Concurrent vasodilators (e.g., nitroglycerin): risk of severe hypotension. - Antiarrhythmic agents (e.g., amiodarone): potential for pro‑arrhythmic events.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt the desired inotropic response. - Diuretics: can exacerbate electrolyte shifts and volume depletion. - Anticoagulants: monitor bleeding risk due to possible platelet effects.